BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8641893)

  • 1. [Immunology of melanoma].
    Bröcker EB; Becker JC
    Hautarzt; 1995 Nov; 46(11):818-28. PubMed ID: 8641893
    [No Abstract]   [Full Text] [Related]  

  • 2. Peptide vaccine trials for melanoma: preclinical background and clinical results.
    Talebi T; Weber JS
    Semin Cancer Biol; 2003 Dec; 13(6):431-8. PubMed ID: 15001162
    [No Abstract]   [Full Text] [Related]  

  • 3. [Immunotherapy for melanoma: how can tolerance be overcome?].
    Robert C
    Ann Dermatol Venereol; 2001; 128(6-7):709-13. PubMed ID: 11460031
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunotherapy of melanoma.
    Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
    Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Future of malignant stage I melanoma. Immunology and immunotherapy].
    Nicolas JF; Berthier O; Trillet-Lenoir V; Claudy A; Revillard JP
    Ann Dermatol Venereol; 1995; 122(5):324-35. PubMed ID: 8572476
    [No Abstract]   [Full Text] [Related]  

  • 6. [Immunology of melanoma].
    Vanwijck R; Bernheim JL; Lejeune FJ
    Acta Chir Belg; 1974 Mar; 73(2):135-88. PubMed ID: 4615541
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cytotoxic T-cell immune response against melanoma antigens].
    Ayyoub M
    Ann Dermatol Venereol; 1998 Nov; 125 Suppl 2():S34-6. PubMed ID: 9922891
    [No Abstract]   [Full Text] [Related]  

  • 8. Induction of tolerance in autoimmune diseases rather than cure of cancer by interleukin-2 therapy.
    Dejaco C; Duftner C; Schirmer M
    J Clin Oncol; 2006 Jul; 24(20):e34; author reply e35-6. PubMed ID: 16829643
    [No Abstract]   [Full Text] [Related]  

  • 9. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use.
    Engelhard VH; Bullock TN; Colella TA; Mullins DW
    Cancer J; 2000 May; 6 Suppl 3():S272-80. PubMed ID: 10874498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
    Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
    Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
    Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
    Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of interleukin-12 receptor on peripheral blood mononuclear cells and HLA class I, HLA class II or ICAM-1 on melanoma cells by B7.1 and interleukin-12: a mechanism for immunostimulatory impact of melanoma cells adenovirally transfected with B7.1 and IL12?
    Yue FY; Cao L; Hemmi S; Geertsen R; Laine E; Burg G; Dummer R
    Melanoma Res; 2000 Aug; 10(4):313-22. PubMed ID: 10985665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active-specific immunization against melanoma: is the problem at the receiving end?
    Monsurrò V; Wang E; Panelli MC; Nagorsen D; Jin P; Katia Z; Smith K; Ngalame Y; Even J; Marincola FM
    Semin Cancer Biol; 2003 Dec; 13(6):473-80. PubMed ID: 15001166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A malignus melanoma immunterápiájának lehetoségei].
    Ladányi A
    Magy Onkol; 2003; 47(1):113-7. PubMed ID: 12704464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma, immune surveillance, and immunotherapy.
    Ferrone S
    J Clin Invest; 1994 Apr; 93(4):1351-2. PubMed ID: 8163637
    [No Abstract]   [Full Text] [Related]  

  • 16. Suppression of immune surveillance in melanoma.
    Biggs MW; Eiselein JE
    Med Hypotheses; 2001 Jun; 56(6):648-52. PubMed ID: 11399114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy of advanced or metastatic melanoma.
    Cebon J; Gedye C; John T; Davis ID
    Clin Adv Hematol Oncol; 2007 Dec; 5(12):994-1006. PubMed ID: 18277962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-G expression in malignant melanoma.
    Rebmann V; Wagner S; Grosse-Wilde H
    Semin Cancer Biol; 2007 Dec; 17(6):422-9. PubMed ID: 17689098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunology of malignant melanoma].
    Misgeld V
    Hautarzt; 1973 Dec; 24(12):511-9. PubMed ID: 4599321
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of immunotherapy in the treatment of melanoma.
    Faries MB
    Surg Oncol Clin N Am; 2006 Apr; 15(2):399-418. PubMed ID: 16632223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.